Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium butyrate is the sodium salt of butyric acid, a short-chain fatty acid naturally produced in the human gut through fermentation of dietary fiber by probiotic bacteria[5][8]. It is used primarily as a dietary supplement and research compound. Sodium butyrate acts as an inhibitor of class I histone deacetylases (HDACs), particularly HDAC1, HDAC2, and HDAC3[2][5][6]. This inhibition leads to hyperacetylation of histones, resulting in altered gene expression patterns that can induce cell cycle arrest and differentiation in mammalian cells[2][5]. Additionally, it activates free fatty acid receptors 2 and 3 (FFAR2/FFAR3), influencing cellular signaling pathways relevant to metabolism and immune function[6]. Sodium butyrate has been studied for its potential benefits on gut health, insulin sensitivity, inflammation reduction, intestinal barrier integrity, and possible roles in metabolic disorders such as obesity or diabetes[4][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium butyrate.